Last edition
News about "US FDA-approved therapies"
Hoth Therapeutics Expands Phase IIa CLEER-001 Trial with New Miami Site
Hoth Therapeutics, Inc. has expanded its Phase IIa CLEER-001 trial with a new Miami site after promising interim results for HT-001 in managing skin toxicities linked to EGFR inhibitor cancer therapy.
US FDA-approved Therapies | 26/02/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members